Cholangiocarcinoma. Epidemiology, classification, diagnosis, treatment methods (literature review)

Alexandra G. Zamotina , Natalia A. Falaleeva , Valery V. Kucherov , Leonid O. Petrov , Artur P. Petrosyan , Artem A. Vovchenko

For citation:

Abstract

Cholangiocarcinoma ranks second in the prevalence among primary malignant neoplasms of the liver. The paper discusses epidemiology, classification, risk factors of the disease, as well as the treatment approaches used all over the world, including surgical and interventional techniques, and drug therapy of the locally advanced and metastatic cholangiocarcinoma.

Keywords: cholangiocarcinoma, etiology, epidemiology, diagnosis, treatment, literature review.

References

1. International classification of diseases for oncology: ICD-O. Geneva: WHO; 2000. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215e29. PMID: 24140396.

2. Khan SA, Davidson BR, Goldin RD et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657-69.

3. Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О.Шахзадовой. М., 2022. The state of cancer care for the Russian population in 2021. Edited by A.D. Kaprin, V.V. Starinsky, A.O.Shakhzadova. Moscow, 2022 (in Russian).

4. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353.

5. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2(10).

6. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173-84.

7. Kaewpitoon N, Kaewpitoon SJ, Pengsaa P, Sripa B. Opisthorchis viverrini: the carcinogenic human liver fluke. World J Gastroenterol. 2008;14(5):666-74.

8. Shin HR, Oh JK, Lim MK et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010;25(7):1011-6.

9. Voyles CR, Smadja C, Shands WC, Blumgart LH. Carcinoma in choledochal cysts. Age-related incidence. Arch Surg. 1983;118(8):986-8.

10. Welzel TM, Graubard BI, El-Serag HB et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5(10):1221-8.

11. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006;3(1):33-42.

12. Rizvi S, Eaton JE, Gores GJ. Primary sclerosing cholangitis as a pre-malignant biliary tract disease: surveillance and management, Clin Gastroenterol Hepatol. 2015;13(12):2152-65.

13. Kim SA, Lee JM, Lee KB et al. Intrahepatic massforming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern – correlation with clinicopathologic findings. Radiology. 2011;260:148-57.

14. Valls C, Guma A, Puig I et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom. Imaging. 2000;25:490-6.

15. Ringe KI, Wacker F. Radiological diagnosis in cholangiocarcinoma: Application of computed tomography, magnetic resonance imaging, and positron emission tomography. Best Pract Res Clin. Gastroenterol. 2015;29:253-65.

16. Weber SM, Ribero D, O'Reilly EM et al. Intrahepatic Cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:669-80.

17. Goere D, Wagholikar GD, Pessaux P et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc. 2006;20:721-5.

18. Spolverato G, Vitale A, Cucchetti A et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer. 2015;21(22):3998-4006. DOI: 10.1002/cncr.29619

19. Tan JC, Coburn NG, Baxter N et al. Surgical management of intrahepatic cholangiocarcinoma – a population-based study. Ann Surg Oncol. 2008;15:600-8.

20. Ercolani G, Dazzi A, Giovinazzo F et al. Intrahepatic, peri-hilar and distal cholangiocarcinoma: Three different locations of the same tumor or three different tumors? Eur J Surg Oncol. 2015;41:1162-9.

21. de Jong MC, Nathan H, Sotiropoulos GC et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140-5.

22. Endo I, Gonen M, Yopp AC et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248:84-96.

23. Boehm LM, Jayakrishnan TT, Miura JT et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111:213-20.

24. Wu ZF, Zhang HB, Yang N et al. Postoperative adjuvant transcatheter arterial chemoembolisation improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors: results of a large monocentric series. Eur J Surg Oncol. 2012;38:602-10.

25. Park SY, Kim JH, Yoon HJ et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol. 2011;66:322-8.

26. G Poggi, A Amatu, B Montagna et al. OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2009;32:1187-92.

27. Kuhlmann JB, Euringer W, Spangenberg HC et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24:437-3.

28. Kim JH, Won HJ, Shin YM et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. Am J Roentgenol. 2011;196:W205-209.

29. Valle J, Wasan H, Palmer DH et al. A.B.C.T. Investigators, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.

30. Oh D-Y, He AR, Qin S et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol 2022;40:378. DOI: 10.1200/JCO.2022.40.4_suppl.378

31. Krook MA, Lenyo A, Wilberding M et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Ther. 2020;19:847-57.

32. Goyal L, Shi L, Liu LY et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;(9):1064-79.

33. Abou-Alfa GK, Macarulla T, Javle MM et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796-807. DOI: 10.1016/S1470-2045(20)30157-1

34. Zhu AX, Macarulla T, Javle MM et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. J Clin Oncol. 2021;39:266. DOI: 10.1200/JCO.2021.39.3_suppl.266.

35. Demols A, Perez-Casanova L, Rocq L et al. 71P NTRK gene fusions in bilioancreatic cancers. Ann Oncol. 2020;31:S268. DOI: 10.1016/j.annonc.2020.08.049

36. Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378:731-9. DOI: 10.1056/NEJMoa1714448

37. Lee J, Park SH, Chang HM J et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:181-8.

38. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies, J Clin Oncol. 2010;28:3531-40.

For citation:Zamotina A.G., Falaleeva N.A., Kucherov V.V., Petrov L.O., Petrosyan A.P., Vovchenko A.A. cholangiocarcinoma. epidemiology, classification, diagnosis, treatment methods (literature review). Clinical review for general practice. 2024; 5 (7): (In russ.). doI: 10.47407/kr2024.5.7.00443

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice